Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational studyRosa Ruchlemer, Tamar Lachish, Ronen Ben‐Ami et al.|Mycoses|2019Cited by 80
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Paolo Abada et al.|The Lancet Haematology|2024Cited by 37
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N. Shah, Jennifer R. Brown, Michael Wang et al.|Haematologica|2024Cited by 12